232 related articles for article (PubMed ID: 32641749)
1. PIM2 promotes hepatocellular carcinoma tumorigenesis and progression through activating NF-κB signaling pathway.
Tang X; Cao T; Zhu Y; Zhang L; Chen J; Liu T; Ming X; Fang S; Yuan YF; Jiang L; Huang JD; Guan XY
Cell Death Dis; 2020 Jul; 11(7):510. PubMed ID: 32641749
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
[TBL] [Abstract][Full Text] [Related]
3. PLK1/NF-κB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression.
Tian L; Yao K; Liu K; Han B; Dong H; Zhao W; Jiang W; Qiu F; Qu L; Wu Z; Zhou B; Zhong M; Zhao J; Qiu X; Zhong L; Guo X; Shi T; Hong X; Lu S
Oncogene; 2020 Apr; 39(15):3145-3162. PubMed ID: 32060423
[TBL] [Abstract][Full Text] [Related]
4. Pim-2 activates API-5 to inhibit the apoptosis of hepatocellular carcinoma cells through NF-kappaB pathway.
Ren K; Zhang W; Shi Y; Gong J
Pathol Oncol Res; 2010 Jun; 16(2):229-37. PubMed ID: 19821157
[TBL] [Abstract][Full Text] [Related]
5. c-Src promotes the growth and tumorigenesis of hepatocellular carcinoma via the Hippo signaling pathway.
Yang J; Zhang X; Liu L; Yang X; Qian Q; Du B
Life Sci; 2021 Jan; 264():118711. PubMed ID: 33186566
[TBL] [Abstract][Full Text] [Related]
6. STK17B promotes carcinogenesis and metastasis via AKT/GSK-3β/Snail signaling in hepatocellular carcinoma.
Lan Y; Han J; Wang Y; Wang J; Yang G; Li K; Song R; Zheng T; Liang Y; Pan S; Liu X; Zhu M; Liu Y; Meng F; Mohsin M; Cui Y; Zhang B; Subash S; Liu L
Cell Death Dis; 2018 Feb; 9(2):236. PubMed ID: 29445189
[TBL] [Abstract][Full Text] [Related]
7. FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via Akt signaling in hepatocellular carcinoma.
Zhang ZQ; Chen J; Huang WQ; Ning D; Liu QM; Wang C; Zhang L; Ren L; Chu L; Liang HF; Fan HN; Zhang BX; Chen XP
Mol Oncol; 2019 Apr; 13(4):792-810. PubMed ID: 30556279
[TBL] [Abstract][Full Text] [Related]
8. Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF-κB pathway.
Tey SK; Tse EYT; Mao X; Ko FCF; Wong AST; Lo RC; Ng IO; Yam JWP
Cancer Lett; 2017 Dec; 411():150-161. PubMed ID: 28989054
[TBL] [Abstract][Full Text] [Related]
9. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
Zhang C; Wang X; Fang D; Xu P; Mo X; Hu C; Abdelatty A; Wang M; Xu H; Sun Q; Zhou G; She J; Xia J; Hui KM; Xia H
Theranostics; 2021; 11(5):2108-2122. PubMed ID: 33500714
[No Abstract] [Full Text] [Related]
10. NCAPG2 overexpression promotes hepatocellular carcinoma proliferation and metastasis through activating the STAT3 and NF-κB/miR-188-3p pathways.
Meng F; Zhang S; Song R; Liu Y; Wang J; Liang Y; Wang J; Han J; Song X; Lu Z; Yang G; Pan S; Li X; Liu Y; Zhou F; Wang Y; Cui Y; Zhang B; Ma K; Zhang C; Sun Y; Xin M; Liu L
EBioMedicine; 2019 Jun; 44():237-249. PubMed ID: 31176678
[TBL] [Abstract][Full Text] [Related]
11. IGFBP2 upregulates ZEB1 expression and promotes hepatocellular carcinoma progression through NF-κB signaling pathway.
Guo Q; Yu DY; Yang ZF; Liu DY; Cao HQ; Liao XW
Dig Liver Dis; 2020 May; 52(5):573-581. PubMed ID: 31818638
[TBL] [Abstract][Full Text] [Related]
12. URG4/URGCP enhances the angiogenic capacity of human hepatocellular carcinoma cells in vitro via activation of the NF-κB signaling pathway.
Xing S; Zhang B; Hua R; Tai WC; Zeng Z; Xie B; Huang C; Xue J; Xiong S; Yang J; Liu S; Li H
BMC Cancer; 2015 May; 15():368. PubMed ID: 25947641
[TBL] [Abstract][Full Text] [Related]
13. CARMA3/NF-κB signaling contributes to tumorigenesis of hepatocellular carcinoma and is inhibited by sodium aescinate.
Hou H; Li WX; Cui X; Zhou DC; Zhang B; Geng XP
World J Gastroenterol; 2019 Sep; 25(36):5483-5493. PubMed ID: 31576094
[TBL] [Abstract][Full Text] [Related]
14. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
Sass G; Klinger N; Sirma H; Hashemolhosseini S; Hellerbrand C; Neureiter D; Wege H; Ocker M; Tiegs G
Int J Oncol; 2011 Aug; 39(2):433-42. PubMed ID: 21567083
[TBL] [Abstract][Full Text] [Related]
17. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
18. PIGU promotes hepatocellular carcinoma progression through activating NF-κB pathway and increasing immune escape.
Wei X; Yang W; Zhang F; Cheng F; Rao J; Lu L
Life Sci; 2020 Nov; 260():118476. PubMed ID: 32971102
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal activation between ATPase inhibitory factor 1 and NF-κB drives hepatocellular carcinoma angiogenesis and metastasis.
Song R; Song H; Liang Y; Yin D; Zhang H; Zheng T; Wang J; Lu Z; Song X; Pei T; Qin Y; Li Y; Xie C; Sun B; Shi H; Li S; Meng X; Yang G; Pan S; Zhu J; Qi S; Jiang H; Zhang Z; Liu L
Hepatology; 2014 Nov; 60(5):1659-73. PubMed ID: 25042864
[TBL] [Abstract][Full Text] [Related]
20. Hypo-phosphorylated CD147 promotes migration and invasion of hepatocellular carcinoma cells and predicts a poor prognosis.
Jin J; Wang SJ; Cui J; Li L; Li JY; Liu FL; Sun XX; Jiang JL; Cui HY; Chen ZN
Cell Oncol (Dordr); 2019 Aug; 42(4):537-554. PubMed ID: 31016558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
